- In my previous article, questions were raised about differences between in vitro and in vivid experimental results, and early-onset and late-onset Alzheimer’s.
- I address these challenging questions using Eli Lilly’s gamma-secretase inhibitor which failed to slow the pace of decline in cognition and functionality in clinical trials despite reductions of amyloid-beta.
- Neither experimental early-onset mutations nor late-onset clinical trials support Cassava Sciences’ hypothesis - amyloid-beta being a causal factor for Alzheimer’s.
- Given the contradictory data from both experimental and clinical trials, I expect drug candidate sumifilam to fail phase 3 clinical trials currently underway.
For further details see:
Cassava Sciences' Hypothesis Contradicts Eli Lilly's Gamma-Secretase Inhibitor Clinical Results